These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12491689)

  • 1. [The relationships of PSA, FPSAR, clinical and pathological stage in patients with prostate cancer].
    Liu HL; Wang H; Yang XJ; Chen BQ; Qin RL; Shao GX
    Zhonghua Nan Ke Xue; 2002; 8(4):261-3. PubMed ID: 12491689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
    Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
    Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS
    J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    J Urol; 1997 Feb; 157(2):544-7. PubMed ID: 8996352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
    Jones TD; Koch MO; Bunde PJ; Cheng L
    BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
    Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
    BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF; Regan MM; Olumi AF; DeWolf WC
    J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical prostatectomy in patients with pT3aN0 prostate cancer.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Ohkubo Y; Suyama T; Komai Y; Kijima T; Ishikawa Y; Fukui I
    Int J Urol; 2008 Oct; 15(10):895-9. PubMed ID: 18721204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.